scholarly journals A multi-center post-marketing surveillance study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A

2005 ◽  
Vol 16 (6) ◽  
pp. 650-663 ◽  
Author(s):  
Katsuyuki FUKUTAKE ◽  
Morio ARAI ◽  
Hiroshi INABA ◽  
Hideji HANABUSA ◽  
Jun-ichi MIMAYA ◽  
...  
Keyword(s):  
Factor Viii ◽  
Hemophilia A ◽  
Recombinant Factor Viii ◽  
Surveillance Study ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Previously Treated Patients ◽  
Previously Treated

A Multicenter Pharmacosurveillance Study for the Evaluation of the Efficacy and Safety of Recombinant Factor VIII in the Treatment of Patients with Hemophilia A

1997 ◽  
Vol 78 (05) ◽  
pp. 1352-1356 ◽  
Author(s):  
Emel Aygören-Pürsün ◽  
Inge Scharrer ◽  
Keyword(s):  
Factor Viii ◽  
Hemophilia A ◽  
Parvovirus B19 ◽  
Subjective Evaluation ◽  
Recombinant Factor Viii ◽  
Fviii Inhibitor ◽  
Previously Treated Patients ◽  
Previously Treated ◽  
Bleeding Episodes ◽  
Recombinant Fviii

SummaryIn this open multicenter study the safety and efficacy of recombinant factor VIII (rFVIII) was assessed in 39 previously treated patients with hemophilia A (factor VIII basal activity ≤15%).Recombinant FVIII was administered for prophylaxis and treatment of bleeding episodes and for surgical procedures. A total of 3679 infusions of rFVIII were given. Efficacy of rFVIII as assessed by subjective evaluation of response to infusion and mean annual consumption of rFVIII was comparable to that of plasma derived FVIII concentrates. The incremental recovery of FVIII (2.4 ± 0,83%/IU/kg, 2.12 ± 0.61%/IU/kg, resp.) was within the expected range. No clinical significant FVIII inhibitor was detected in this trial. Five of 16 susceptible patients showed a seroconversion for parvovirus B19. However, the results are ambiguous in two cases and might be explained otherwise in one further case. Thus, in two patients a reliable seroconversion for parvovirus B19 was observed.

A Post-Marketing Surveillance Study of the Safety and Efficiacy of Refacto® (Moroctocog Alfa, B-Domain Deleted Recombinant Factor VIII) (St. Louis-Derived Active Substance in the Treatment and Prevension of Bleeding Episodes in Hemophilia a Patients.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4023-4023
Author(s):  
Jay M. Feingold ◽  
Mark P. Smith ◽  
Richard Littlewood ◽  
Paul Giangrande ◽  
Keyword(s):  
Factor Viii ◽  
Active Substance ◽  
Hemophilia A ◽  
High Titre ◽  
Surveillance Study ◽  
Point Scale ◽  
On Demand ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Bleeding Episodes

Abstract This was an open-label, multicenter, post-marketing surveillance study conducted in Belgium, France, Germany, Italy, Netherlands, New Zealand, Switzerland, and UK. The objectives were to assess the safety and clinical efficacy of ReFacto St Louis-derived active substance (STL) in the treatment and prevention of bleeding episodes in patients with hemophilia A in the usual care setting. 60 patients with moderate to severe hemophilia A (FVIII:C <5%) with no history of FVIII inhibitor were enrolled (58 were previously treated patients and 2 were previously untreated patients). Data on infusions, concomitant medications, adverse events, and inhibitor development were collected from patients at regular intervals. Efficacy for prophylaxis was assessed by the investigator approximately every 3 months until 50 exposure days, 6 months or study termination using the number of breakthrough bleeding episodes and the 3-point scale (excellent, effective, and inadequate). The efficacy of each on-demand treatment administered was assessed using the 4-point scale (excellent, good, moderate, and no response). The investigator and surgeon assessed efficacy of surgical prophylaxis jointly after each surgery using the 4-point scale (excellent, good, moderate, and no response). Factor VIII inhibitor (using local laboratory Bethesda assay) was evaluated at screening, after 10 EDs, after 30 EDs, and at the end of treatment. The investigator determined all dosing and treatment regimens. In the prophylaxis treatment group, no particular prophylaxis regimen was enforced. A total of 32 patients aged 0–66 years initially received prophylaxis treatment: 10 (31%) patients reported no breakthrough bleeds. A median of 6.25 bleeds per year occurred in all prophylaxis patients. Twenty-nine assessments of the prophylactic treatment final outcome were made: 93% of these assessments were excellent or effective. A total of 28 patients aged 1–71 years initially received on-demand treatment with ReFacto STL. 95.2% of bleeds were resolved with 1 or 2 infusions. The assessment of treatment response was excellent or good in 98% of cases. Seven patients underwent 7 surgical procedures, haemostasis was achieved all cases and ReFacto STL was rated as providing an excellent or good response as the final outcome in each case. As this was a post-marketing study, safety evaluation was focused on collection of serious AEs and product-related non-serious AEs. One PTP (1/58, 1.7%) developed a high titre inhibitor and 1/58 (1.7%) developed a low titre transient inhibitor. One PUP developed a low titre transient inhibitor (0.4 BU). SAEs included 1 fatal intracranial hemorrhage (considered unrelated to ReFacto), 5 preplanned surgeries, 1 episode of gastroenteritis, and 1 hemorrhage. There were no allergic events. Three patients were withdrawn from treatment for safety reasons (1 patient due to death, 1 PTP due to high titre inhibitor and 1 PTP due to low titre transient inhibitor). The nature and incidence of non-serious AEs did not raise new safety concerns. The majority of AEs were mild or moderate in severity.

Sign in / Sign up

Export Citation Format

Share Document